New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents

Clin Exp Rheumatol. 2008 May-Jun;26(3 Suppl 49):S141-50.

Authors

E Lozano¹, M Segarra, A García-Martínez, G Espígol-Frigolé, J Hernández-Rodríguez, M C Cid

Affiliation

¹ Department of Systemic Autoimmune Diseases, Clinical Institute of Medicine and Dermatology, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques, Barcelona, Spain.

PMID: 18799072

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Design*
Giant Cell Arteritis / drug therapy*
Giant Cell Arteritis / physiopathology*
Humans
Polymyalgia Rheumatica / drug therapy
Polymyalgia Rheumatica / physiopathology
Tumor Necrosis Factor-alpha / immunology

Substances

Tumor Necrosis Factor-alpha